Imagine a world where every lab, regardless of size or budget, has access to cutting-edge proteomics technology. Sounds like a dream, right? Well, that dream is getting closer to reality. At Olink, our unwavering mission has been to democratize high-quality proteomics, making it accessible to researchers everywhere. And today, we’re thrilled to announce a significant leap forward: Olink® Reveal is now fully verified for sequencing on MGI T1+ and G400 platforms, complete with optimized protocols and proven performance. Read more here.
But here’s where it gets exciting: This breakthrough isn’t just about compatibility—it’s about expanding the horizons of next-generation proteomics. By enabling more labs to generate reliable, high-quality protein data through a streamlined NGS-based workflow, we’re empowering researchers to explore disease biology with unprecedented depth. And this is the part most people miss: the carefully curated panel of ~1,000 proteins isn’t just data—it’s a treasure trove of actionable biological insights waiting to be uncovered.
But here’s where it gets controversial: As proteomics becomes more accessible, questions arise about how labs will handle the influx of data and whether smaller teams have the resources to fully leverage these advancements. Is this a step toward true democratization, or does it risk widening the gap between well-funded and under-resourced labs? We’d love to hear your thoughts in the comments.
This milestone is another bold stride toward our vision: a world where high-quality proteomics is within reach for every lab, everywhere. Because when more researchers have access to powerful tools, the potential for groundbreaking discoveries grows exponentially. So, what do you think? Are we on the right track, or is there more to be done? Let’s start the conversation.
Citations
If you’re referencing this article, here’s how to cite it in various formats:
- APA: Olink®- Part of Thermo Fisher Scientific. (2025, November 13). Bringing accessible NGS-based proteomics to even more labs. News-Medical. Retrieved November 13, 2025, from https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx.
- MLA: Olink®- Part of Thermo Fisher Scientific. "Bringing accessible NGS-based proteomics to even more labs." News-Medical, 13 Nov. 2025, https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx.
- Chicago: Olink®- Part of Thermo Fisher Scientific. "Bringing accessible NGS-based proteomics to even more labs." News-Medical. https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx (accessed November 13, 2025).
- Harvard: Olink®- Part of Thermo Fisher Scientific. 2025. Bringing accessible NGS-based proteomics to even more labs. News-Medical. Available at: https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx [Accessed November 13, 2025].
Terms & Conditions
While Azthena answers are based on edited and approved content, occasional inaccuracies may occur. Always verify data with the original suppliers or authors. For medical inquiries, consult a healthcare professional. Your questions (not email details) will be shared with OpenAI and retained for 30 days. Avoid sharing sensitive information. For full details, review our Terms & Conditions.
